Syros Pharmaceuticals Inc. logo

SYRS

Syros Pharmaceuticals Inc.

$0.9

Earnings Summary

Revenue
$5.47Mn
Net Profits
$-25.15Mn
Net Profit Margins
-459.96%

Highlights

Revenue:

Syros Pharmaceuticals Inc.’s revenue jumped 13.26% since last year same period to $5.47Mn in the Q1 2022. On a quarterly growth basis, Syros Pharmaceuticals Inc. has generated -29.93% fall in its revenue since last 3-months.

Net Profits:

Syros Pharmaceuticals Inc.’s net profit fell -76.74% since last year same period to $-25.15Mn in the Q1 2022. On a quarterly growth basis, Syros Pharmaceuticals Inc. has generated -5.6% fall in its net profits since last 3-months.

Net Profit Margins:

Syros Pharmaceuticals Inc.’s net profit margin fell -56.05% since last year same period to -459.96% in the Q1 2022. On a quarterly growth basis, Syros Pharmaceuticals Inc. has generated -50.7% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Syros Pharmaceuticals Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-0.41
EPS Estimate Current Year
-0.41

Highlights

EPS Estimate Current Quarter:

Syros Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.41 - a 12.77% jump from last quarter’s estimates.

EPS Estimate Current Year:

Syros Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at -0.41.

Key Ratios

Key ratios of the Syros Pharmaceuticals Inc. post its Q1 2022 earnings

Earning Per Share (EPS)
-0.4
Return on Assets (ROA)
-0.31
Return on Equity (ROE)
-0.98
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Syros Pharmaceuticals Inc.’s earning per share (EPS) fell -73.91% since last year same period to -0.4 in the Q1 2022. This indicates that the Syros Pharmaceuticals Inc. has generated -73.91% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Syros Pharmaceuticals Inc.’s return on assets (ROA) stands at -0.31.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Syros Pharmaceuticals Inc.’s return on equity (ROE) stands at -0.98.

Dividend Per Share (DPS):

Syros Pharmaceuticals Inc. declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-0.47
-0.4
14.89%

Company Information

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Organisation
Syros Pharmaceuticals Inc.
Headquarters
Cambridge, Massachusetts, US
Employees
103
Industry
Health Technology
CEO
Nancy Simonian